MedTrace Logo

Safety Study of Vx006 Vaccine in Solid Tumor Patients

NCT02289196 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2019-06-19

No results posted yet for this study

Summary

Patients with histologically proven malignancy with documented disease control (objective response or stable disease) or Not Evaluable Disease (NED) expectancy \> 6 months; only HLA-A\*02 positive patients.

The primary objective of the trial is to compare safety and tolerability of four different doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses of the Vx-006.

Conditions

Interventions

DRUG

Vx-006: 0,5mg

DRUG

Vx-006: 1mg

DRUG

Vx-006: 5mg

DRUG

Vx-006: 10mg

Sponsors & Collaborators

  • Vaxon Biotech

    lead INDUSTRY

Principal Investigators

  • Katsaounis Panagiotis, MD, PhD · Iaso General Hospital, Athens

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-10-31
Completion
2017-05-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02289196 on ClinicalTrials.gov